Agency
Avalon Client Services, LLC
Avalon Client Services, LLC was paid $50K by Medicaid between Jul 2021 and Oct 2024, across 47 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 60% of everything it billed.
33Billing provider infoAVALON CLIENT SERVICES, LLC
TAMPA, FL 33607
TAMPA, FL 33607
33aNPI1902348626assigned 11/11/2016
33bProvider typeCase Management Agency
28Total paid$50K
24GClaims10,784
24DCodes billed47
24AFirst – last monthJul 2021 – Oct 2024
Compared with peers
Next to other Case Management Agency providers in Florida
Rank by total paid#312 of 357
Median peer was paid$839K
This provider vs. median0.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 3,217 | $14K | |
| 2022 | 6,329 | $23K | |
| 2023 | 817 | $10K | |
| 2024incomplete | 421 | $3K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 60% | 3,325 | 3,030 | $30K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 18% | 1,294 | 1,003 | $9K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 12% | 3,020 | 2,749 | $6K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 8.8% | 1,056 | 820 | $4K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.6% | 15 | 12 | $769.65 |
| 36415 | Collection of venous blood by venipuncture | <1% | 261 | 253 | $28.56 |
| 80061 | Lipid panel | <1% | 167 | 166 | $6.04 |
| 83550 | 0% | 13 | 13 | $0.00 | |
| 84479 | 0% | 14 | 14 | $0.00 | |
| 86592 | 0% | 50 | 50 | $0.00 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 0% | 69 | 69 | $0.00 |
| 87581 | 0% | 26 | 26 | $0.00 |
35 more codes
| 87081 | 0% | 21 | $0.00 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 0% | 23 | $0.00 |
| 82728 | 0% | 20 | $0.00 | |
| 82043 | 0% | 13 | $0.00 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 0% | 71 | $0.00 |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 0% | 22 | $0.00 |
| 80048 | Basic metabolic panel (calcium, ionized) | 0% | 14 | $0.00 |
| 87070 | 0% | 12 | $0.00 | |
| 84436 | 0% | 16 | $0.00 | |
| 80053 | Comprehensive metabolic panel | 0% | 157 | $0.00 |
| 83735 | 0% | 13 | $0.00 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 0% | 46 | $0.00 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 0% | 94 | $0.00 |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 0% | 86 | $0.00 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 0% | 17 | $0.00 |
| 83036 | Hemoglobin; glycosylated (A1C) | 0% | 120 | $0.00 |
| 85027 | 0% | 41 | $0.00 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 0% | 76 | $0.00 |
| 84443 | Thyroid stimulating hormone (TSH) | 0% | 105 | $0.00 |
| 80050 | General health panel | 0% | 49 | $0.00 |
| 87077 | 0% | 14 | $0.00 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 0% | 16 | $0.00 |
| 87088 | 0% | 24 | $0.00 | |
| 82607 | 0% | 21 | $0.00 | |
| 86803 | 0% | 14 | $0.00 | |
| 84439 | 0% | 81 | $0.00 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 0% | 96 | $0.00 |
| 83655 | 0% | 15 | $0.00 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 0% | 45 | $0.00 |
| 82570 | 0% | 13 | $0.00 | |
| 87186 | 0% | 24 | $0.00 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 0% | 24 | $0.00 |
| 83540 | 0% | 19 | $0.00 | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 0% | 34 | $0.00 |
| 84702 | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMORGAN, STEVEN (GENERAL COUNSEL)
| Provider | Location | Paid |
|---|---|---|
| Onondaga County Comptrollers Office | Syracuse, NY | $7.60M |
| Onondaga County Comptrollers Office | Syracuse, NY | $389K |
| Patients' Choice Home Healthcare Corporation | Chesapeake, VA | $292K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.